183 related articles for article (PubMed ID: 23179336)
1. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
Hong DS; Choe JH; Naing A; Wheler JJ; Falchook GS; Piha-Paul S; Moulder SL; George GC; Choe JM; Strauss LC; Gallick GE; Kurzrock R
Invest New Drugs; 2013 Aug; 31(4):918-26. PubMed ID: 23179336
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
[TBL] [Abstract][Full Text] [Related]
3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
4. A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
Raymond E; Alexandre J; Faivre S; Goldwasser F; Besse-Hammer T; Gianella-Borradori A; Jego V; Trandafir L; Rejeb N; Awada A
Invest New Drugs; 2014 Feb; 32(1):94-103. PubMed ID: 23539344
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
Takahashi S; Miyazaki M; Okamoto I; Ito Y; Ueda K; Seriu T; Nakagawa K; Hatake K
Cancer Sci; 2011 Nov; 102(11):2058-64. PubMed ID: 21781226
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
Argiris A; Feinstein TM; Wang L; Yang T; Agrawal S; Appleman LJ; Stoller RG; Grandis JR; Egloff AM
Invest New Drugs; 2012 Aug; 30(4):1575-84. PubMed ID: 21881918
[TBL] [Abstract][Full Text] [Related]
7. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial.
Cardin DB; Goff LW; Chan E; Whisenant JG; Dan Ayers G; Takebe N; Arlinghaus LR; Yankeelov TE; Berlin J; Merchant N
Invest New Drugs; 2018 Jun; 36(3):442-450. PubMed ID: 28990119
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.
Aspeslagh S; Shailubhai K; Bahleda R; Gazzah A; Varga A; Hollebecque A; Massard C; Spreafico A; Reni M; Soria JC
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1257-1265. PubMed ID: 28424962
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
11. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Lim N; Lara PN; Lau DH; Edelman MJ; Tanaka M; al-Jazayrly G; Houston J; Lauder I; Gandara DR
Cancer Invest; 2003; 21(1):7-13. PubMed ID: 12643004
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
Chan E; Chiorean EG; O'Dwyer PJ; Gabrail NY; Alcindor T; Potvin D; Chao R; Hurwitz H
Cancer Chemother Pharmacol; 2018 Feb; 81(2):355-364. PubMed ID: 29238851
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
Bommakanti SV; Dudek AZ; Khatri A; Kirstein MN; Gada PD
Am J Clin Oncol; 2011 Dec; 34(6):597-602. PubMed ID: 21127410
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Somlo G; Atzori F; Strauss LC; Geese WJ; Specht JM; Gradishar WJ; Rybicki A; Sy O; Vahdat LT; Cortes J
Clin Cancer Res; 2013 Apr; 19(7):1884-93. PubMed ID: 23403636
[TBL] [Abstract][Full Text] [Related]
17. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Starling N; Hawkes EA; Chau I; Watkins D; Thomas J; Webb J; Brown G; Thomas K; Barbachano Y; Oates J; Cunningham D
Ann Oncol; 2012 Apr; 23(4):942-7. PubMed ID: 21750117
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Secord AA; Teoh DK; Barry WT; Yu M; Broadwater G; Havrilesky LJ; Lee PS; Berchuck A; Lancaster J; Wenham RM
Clin Cancer Res; 2012 Oct; 18(19):5489-98. PubMed ID: 22837181
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]